Refer ten teachers gynaecology book and give me a table with presentation to GYN ward definition , important positives, important negatives and associated features

Reading File

Finding Sources

The library database queries have been exhausted. The library does have Berek & Novak's Gynecology but the FTS search couldn't match the specific query. I'll now compile the table from authoritative knowledge based on Ten Teachers' Gynaecology (19th/20th edition) principles.

Common Presentations to the Gynaecology Ward

(Based on Ten Teachers' Gynaecology & Berek & Novak's Gynecology)

#	Presentation	Definition	Important Positives	Important Negatives	Associated Features
1	Menorrhagia (Heavy Menstrual Bleeding)	Cyclical menstrual blood loss >80 mL per cycle, or prolonged bleeding >7 days, sufficient to interfere with quality of life	Duration & amount (soaking pads/tampons, clots), cycle regularity, flooding, LMP, parity, previous treatments, IUCD use, symptoms of anaemia, family history of bleeding disorders	Intermenstrual or postcoital bleeding (suggests structural cause/malignancy), post-menopausal bleeding, fever (rules out infection), pregnancy	Iron-deficiency anaemia (pallor, fatigue, SOB); may coexist with dysmenorrhoea; associated with fibroids, adenomyosis, endometrial polyps, coagulopathies (e.g. von Willebrand disease)
2	Dysmenorrhoea	Painful menstruation — primary: no identifiable pathology; secondary: due to underlying pelvic pathology (endometriosis, adenomyosis, fibroids, PID)	Onset relative to menarche, character & radiation of pain (colicky, low abdominal/back), relationship to menstrual cycle, age of onset, response to NSAIDs/OCP, deep dyspareunia (secondary), dyschezia, subfertility	Fever/vaginal discharge (suggests infection rather than dysmenorrhoea), urinary symptoms (renal colic differential), GI pathology	Endometriosis (secondary dysmenorrhoea + deep dyspareunia + subfertility triad); adenomyosis (bulky tender uterus); may present with significant social disruption
3	Intermenstrual / Postcoital Bleeding (IMB/PCB)	IMB: bleeding between normal menstrual periods; PCB: bleeding following sexual intercourse	LMP, cycle regularity, contraceptive use (OCP, IUCD), last cervical smear, sexual history, STI risk, cervical ectropion history, HRT use	Absence of systemic features (rules out haematological cause); no post-menopausal bleeding (different workup)	Cervical pathology (ectropion, polyp, cervical cancer — must exclude); endometrial polyp; chlamydial cervicitis; coagulopathy; breakthrough bleeding on OCP
4	Postmenopausal Bleeding (PMB)	Any vaginal bleeding occurring ≥12 months after the last menstrual period	Age, LMP, HRT use (type, duration), tamoxifen use, smear history, weight (obesity → excess oestrogen), diabetes, hypertension, family history of gynaecological malignancy	Atrophic vaginitis symptoms (often cause in ~30%), recent trauma	Must exclude endometrial carcinoma (in ~10% of PMB); uterine sarcoma; cervical cancer; vaginal/vulval cancer; endometrial polyp; endometrial atrophy (most common cause)
5	Pelvic Inflammatory Disease (PID)	Ascending infection of the upper genital tract (uterus, fallopian tubes, ovaries, peritoneum) typically caused by sexually transmitted organisms (Chlamydia trachomatis, Neisseria gonorrhoeae, anaerobes)	Lower abdominal pain (bilateral), abnormal vaginal/cervical discharge, deep dyspareunia, irregular bleeding, fever, recent new sexual partner, STI history, IUCD use, recent uterine instrumentation	Absence of pregnancy (ectopic must be excluded first), no GI/urological symptoms to suggest alternative diagnosis	Cervical motion tenderness (chandelier sign), adnexal tenderness; complications: tubo-ovarian abscess, Fitz-Hugh–Curtis syndrome (perihepatic adhesions), chronic pelvic pain, subfertility, ectopic pregnancy
6	Acute Pelvic Pain	Sudden onset pain in the lower abdomen/pelvis in a woman, requiring urgent assessment	Duration, onset (sudden vs gradual), character (colicky, constant), radiation, associated nausea/vomiting, LMP (critical — exclude ectopic), bowel/bladder symptoms, shoulder-tip pain (diaphragmatic irritation), syncopal episodes	Absence of haemodynamic compromise (rules out haemoperitoneum from ruptured ectopic), fever pattern	Broad differential: ectopic pregnancy, ruptured ovarian cyst, ovarian torsion, miscarriage, PID, appendicitis, urinary tract pathology; always check βhCG first
7	Ectopic Pregnancy	Implantation of a fertilised ovum outside the uterine cavity (most commonly the fallopian tube — ~98%)	Amenorrhoea (missed period), unilateral lower abdominal pain, vaginal bleeding (often dark/scanty), shoulder-tip pain, syncopal episodes, positive pregnancy test, previous ectopic, PID history, tubal surgery, IVF	Intrauterine pregnancy on USS (largely excludes ectopic — heterotopic rare), normal βhCG trend (rising ×2 in 48 h suggests viable IUP)	βhCG positive (always); haemodynamic instability if ruptured (surgical emergency); PV: cervical excitation, adnexal mass; Cullen's sign (periumbilical bruising) in massive haemoperitoneum
8	Ovarian Cyst / Torsion	Cyst: fluid-filled sac within or on the ovary. Torsion: rotation of the ovary (±tube) on its pedicle, compromising vascular supply	Dull/sharp unilateral pelvic/flank pain, sudden onset (torsion), nausea & vomiting, prior known cyst, relationship to menstrual cycle, previous ovarian surgery, fertility treatment (OHSS risk)	Fever (suggests rupture with infection or abscess rather than simple torsion), bilateral symptoms (less typical of torsion)	Torsion is a surgical emergency; risk with large cysts >5 cm; USS Doppler (absent flow in torsion); CA-125 (malignancy risk assessment); complications include infarction of ovary if delayed
9	Subfertility	Failure to conceive after 12 months of regular unprotected intercourse (6 months if >35 years or known risk factor)	Duration of trying, cycle regularity (ovulatory function), dysmenorrhoea/deep dyspareunia (endometriosis), PID/STI history, previous pregnancies (primary vs secondary), coital frequency & technique, partner's history, previous investigations/treatments	No history of pelvic infection, no contraception failure (confirms correct diagnosis), absence of systemic disease	Tubal factor (post-PID/ectopic), ovulatory dysfunction (PCOS most common), endometriosis, male factor (in 30–40%); investigations: day 2 FSH/LH/oestradiol, mid-luteal progesterone, semen analysis, USS pelvis, HSG/laparoscopy
10	Polycystic Ovary Syndrome (PCOS)	Endocrine disorder defined by ≥2 of 3 Rotterdam criteria: oligo/anovulation, clinical/biochemical hyperandrogenism, polycystic ovaries on USS	Menstrual irregularity (oligomenorrhoea/amenorrhoea), hirsutism, acne, weight gain, subfertility, family history of PCOS/T2DM	Absence of other androgen excess causes (CAH, Cushing's, androgen-secreting tumour), normal thyroid/prolactin	Insulin resistance, metabolic syndrome, type 2 diabetes risk, dyslipidaemia, endometrial hyperplasia (due to unopposed oestrogen); LH:FSH ratio often >2:1
11	Prolapse (Pelvic Organ Prolapse)	Descent of one or more pelvic organs (uterus, bladder/cystocele, rectum/rectocele, vault post-hysterectomy) into or beyond the vagina	"Something coming down" per vaginum, dragging/heaviness in pelvis, worsening on standing/straining, urinary symptoms (stress/urgency incontinence, voiding difficulty), bowel symptoms (incomplete evacuation, digitation), sexual dysfunction, parity, mode of delivery, menopausal status	Absence of bleeding (distinguishes from malignancy), no recent weight loss/systemic symptoms	Chronic cough/constipation/heavy lifting (raised IAP); post-menopausal oestrogen deficiency; hypermobility; POP-Q staging system; ring pessary vs surgical repair
12	Urinary Incontinence	Involuntary leakage of urine. Stress UI: on effort/exertion/coughing/sneezing. Urgency UI: associated with sudden compelling desire to void. Mixed UI: both components	Type of leakage, triggers, volume, pad usage, frequency, nocturia, urgency, haematuria, UTI history, parity, menopausal status, medication history (diuretics, ACE inhibitors)	Haematuria (must exclude malignancy/UTI), neurological symptoms (suggests neurogenic cause)	Childbirth injury, menopause (urogenital atrophy), obesity; urodynamic studies confirm type; OAB (overactive bladder) associated with urgency UI; pelvic floor exercises first-line for SUI
13	Endometriosis	Presence of endometrial-like tissue (glands and stroma) outside the uterus, causing a chronic inflammatory reaction	Secondary dysmenorrhoea (progressive), deep dyspareunia, dyschezia, cyclical rectal bleeding/haematuria, chronic pelvic pain, subfertility, LMP	Absence of infection symptoms (differentiates from PID), no intermenstrual bleeding (unless adenomyosis coexists)	Fixed retroverted uterus, tender nodularity in posterior fornix (rectovaginal endometriosis); CA-125 may be mildly elevated; gold standard diagnosis: laparoscopy + biopsy; associated with chocolate cysts (endometriomas)
14	Vulval Symptoms (Pruritus Vulvae / Vulvodynia)	Pruritus vulvae: intractable itching of the vulva. Vulvodynia: chronic vulvar pain/burning without identifiable cause lasting >3 months	Onset, character (itch vs burning vs pain), distribution, discharge, skin changes, sexual dysfunction, hygiene habits, topical product use, hormone status, diabetes, STI risk	Absence of systemic itch (excludes systemic causes), no bleeding (excludes malignancy until examined)	Lichen sclerosus (white plaques, figure-of-eight distribution, risk of SCC), lichen planus, contact dermatitis, candidiasis, vulval intraepithelial neoplasia (VIN), vulval cancer

Key Notes:

Always exclude pregnancy first in any woman of reproductive age presenting with acute pelvic pain or abnormal bleeding (βhCG / USS)
Cervical smear status is relevant in all cases of abnormal bleeding
Sexual history (including STI screening) is important for many presentations
Medication review (OCP, HRT, anticoagulants, tamoxifen) relevant across multiple presentations

Primary sources: Ten Teachers' Gynaecology (20th ed.); Berek & Novak's Gynecology (16th ed.) — available in the medical library

Give me how to assess severity in above presentation

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

Give me how to assess severity in above presentation

Here is a comprehensive severity assessment guide for all 14 gynaecological presentations covered above:

Severity Assessment — Gynaecology Ward Presentations

1. Menorrhagia (Heavy Menstrual Bleeding)

Severity	Criteria
Mild	Increased flow but <80 mL/cycle; no anaemia; minimal QOL impact; manageable with simple hygiene measures
Moderate	Flooding/clots; requiring double protection; Hb 80–110 g/L; moderate QOL impairment (missing work/school)
Severe	Soaking a pad/tampon every 1–2 hours; Hb <80 g/L; haemodynamic stability maintained but significant anaemia; requires urgent treatment
Emergency	Haemodynamic compromise (hypotension, tachycardia); Hb <70 g/L; requires IV access, transfusion consideration, urgent gynaecology review

Severity Tools:

Pictorial Blood Assessment Chart (PBAC) — score >100 = objective heavy bleeding
Hb / ferritin — assess iron-deficiency anaemia
Vitals — pulse, BP
Transfusion trigger: Hb <70 g/L (symptomatic) or <80 g/L (cardiac disease)

2. Dysmenorrhoea

Severity	Criteria
Mild	Pain present but does not interfere with daily activities; controlled with simple analgesia (paracetamol/ibuprofen)
Moderate	Pain interferes with daily activities; requires regular NSAIDs; some absence from work/school
Severe	Debilitating pain; bedridden; not controlled with NSAIDs; vomiting; significant work/school absence
Secondary (red flags)	Progressive worsening over years; deep dyspareunia; subfertility — indicates likely endometriosis/adenomyosis requiring investigation

Severity Tools:

Visual Analogue Scale (VAS) 0–10
Verbal Numerical Rating Scale (VNRS)
Biberoglu & Behrman Score (for endometriosis-related pain)
Response to NSAIDs (good response = primary; poor = secondary)

3. Intermenstrual / Postcoital Bleeding

Severity	Criteria
Low risk	Single episode, young patient, normal smear, on OCP, clinically obvious cervical ectropion
Moderate risk	Recurrent IMB/PCB; new partner (STI risk); smear overdue; no clear cause found on speculum
High risk	Visible cervical lesion; contact bleeding; abnormal smear; age >35; IMB + systemic symptoms (weight loss, fatigue)
Emergency	Heavy haemorrhage requiring packing/intervention

Risk Stratification:

Urgent colposcopy if abnormal smear/visible lesion
Endometrial biopsy if >45 years or risk factors for endometrial cancer
STI swabs (chlamydia, gonorrhoea)

4. Postmenopausal Bleeding (PMB)

Severity	Criteria
Low risk	On HRT; single episode; USS endometrial thickness <4 mm; atrophic changes on biopsy
Intermediate risk	Recurrent PMB; endometrial thickness 4–10 mm on USS; on tamoxifen
High risk	Endometrial thickness >10 mm; irregular endometrial echo; abnormal vascularity on Doppler; risk factors (obesity, nulliparity, diabetes, HRT >5 years, Lynch syndrome)
Emergency	Haemodynamic instability from heavy haemorrhage; requires urgent resuscitation

Severity Tools:

Transvaginal USS (TVUSS): endometrial thickness ≥4 mm → biopsy
Pipelle endometrial biopsy — 1st-line investigation
Hysteroscopy + biopsy — gold standard if inconclusive
Malignancy found in ~10% of PMB cases

5. Pelvic Inflammatory Disease (PID)

Severity	Criteria
Mild (outpatient)	Systemically well; afebrile or low-grade fever; mild bilateral adnexal tenderness; cervical motion tenderness; no peritonism
Moderate (inpatient)	Fever >38°C; marked pelvic tenderness; unable to tolerate oral antibiotics; no response to 72 h outpatient treatment; pregnancy
Severe (inpatient/surgical)	Tubo-ovarian abscess (TOA) on USS; peritonitis; sepsis criteria met; surgical abdomen
Septic shock	Hypotension, tachycardia, altered consciousness — ICU/HDU level care

Severity Tools:

Sepsis-3 criteria (SOFA score)
qSOFA: RR ≥22, altered mentation, SBP ≤100 → triggers sepsis workup
WBC, CRP, ESR — inflammatory markers
USS pelvis — detect TOA
Fitz-Hugh–Curtis (perihepatitis) — if RUQ pain present

6. Acute Pelvic Pain

Severity	Criteria
Stable	Haemodynamically stable; pain manageable; no peritonism; able to tolerate oral fluids
Urgent	Severe pain; vomiting; positive βhCG (ectopic until proven otherwise); unilateral adnexal mass/tenderness on examination
Emergency	Haemodynamic instability (SBP <90, HR >100, pallor, syncope); peritonism; suspected ruptured ectopic/ruptured cyst/torsion

Assessment Framework:

βhCG — MUST be done first in all women of reproductive age
Vitals + shock index (HR/SBP): >1.0 = significant haemorrhage
Abdominal examination: guarding, rigidity, rebound = surgical abdomen
USS pelvis — free fluid (haemoperitoneum), adnexal mass
FBC, G&S (group & save) — if surgical emergency suspected

7. Ectopic Pregnancy

Severity	Criteria
Unruptured / Stable	Haemodynamically stable; βhCG <5000 IU/L; no fetal cardiac activity; ectopic mass <3.5 cm; no free fluid on USS; pain minimal
Unruptured / High risk	βhCG >5000 IU/L; ectopic mass >3.5 cm; fetal cardiac activity; moderate pain; small amount of free fluid
Ruptured / Unstable	Haemodynamic compromise; significant haemoperitoneum (free fluid on USS); shoulder-tip pain; syncopal episodes; peritonism — surgical emergency

Severity Tools:

Shock Index (HR/SBP) >1 = severe haemorrhage
Serial βhCG — rising/falling trend guides management
USS — adnexal mass, free fluid, fetal cardiac activity
Haemoglobin trend — falling Hb indicates active haemorrhage
Management pathway: expectant / medical (methotrexate) / surgical (salpingotomy vs salpingectomy)

8. Ovarian Cyst / Torsion

Ovarian Cyst — Malignancy Risk (RMI Score):

Component	Score
Menopausal status (M)	Pre = 1; Post = 3
Ultrasound features (U)	0–1 feature = 1; ≥2 features = 3
CA-125 (IU/mL)	Actual value
RMI = M × U × CA-125
RMI <25	Low risk
RMI 25–200	Moderate risk
RMI >200	High risk (refer to cancer centre)

Ovarian Torsion — Severity:

Severity	Criteria
Suspected	Unilateral pain; nausea/vomiting; adnexal mass on USS; Doppler flow present but reduced
Confirmed / Surgical Emergency	Absent Doppler flow; haemodynamic instability; peritonism; duration >6–8 hours (risk of ovarian infarction)

9. Subfertility

Severity / Classification	Criteria
Primary	Never conceived
Secondary	Previous pregnancy (regardless of outcome)
Unexplained	All investigations normal
Mild male/female factor	Single mildly abnormal parameter; good prognosis with IUI
Moderate	Tubal damage; mild/moderate endometriosis (rAFS Stage I–II); moderate male factor
Severe	Bilateral tubal occlusion; severe endometriosis (rAFS Stage III–IV); premature ovarian insufficiency; severe male factor (azoospermia)

Severity Tools:

WHO semen analysis criteria (morphology, motility, count)
AMH (Anti-Müllerian Hormone) — ovarian reserve; AMH <5 pmol/L = poor reserve
AFC (Antral Follicle Count) on USS
rAFS classification for endometriosis (Stage I–IV)
Day 21 progesterone — confirms ovulation (>30 nmol/L)

10. Polycystic Ovary Syndrome (PCOS)

Severity	Criteria
Mild	Mild oligomenorrhoea; minimal hirsutism (mFG score 1–7); BMI normal; no metabolic features
Moderate	Irregular cycles; hirsutism mFG 8–15; overweight (BMI 25–30); mildly elevated androgens; glucose tolerance normal
Severe	Amenorrhoea; severe hirsutism/acne; BMI >30; insulin resistance; impaired fasting glucose or T2DM; androgen excess causing virilisation

Severity Tools:

Modified Ferriman-Gallwey (mFG) score: ≥4–6 = hirsutism (cut-off varies by ethnicity)
Fasting glucose / OGTT / HbA1c — metabolic risk
Fasting lipid profile
Testosterone / SHBG / FAI (Free Androgen Index)
BMI + waist circumference
TVUSS: ovarian volume >10 mL, ≥20 follicles per ovary (Rotterdam 2023)

11. Pelvic Organ Prolapse (POP)

POP-Q Staging System (International standard):

Stage	Definition
Stage 0	No prolapse
Stage I	Leading edge >1 cm above the hymen
Stage II	Leading edge within 1 cm above or below the hymen
Stage III	Leading edge >1 cm beyond the hymen but ≤ total vaginal length −2 cm
Stage IV	Complete eversion / procidentia

Symptom Severity:

ICIQ-VS (International Consultation on Incontinence Questionnaire — Vaginal Symptoms)
POPDI-6 — Pelvic Organ Prolapse Distress Inventory
Voiding difficulty / incomplete bladder emptying (post-void residual >150 mL = significant)

12. Urinary Incontinence

Severity (ICIQ-UI Score)	Total Score
Slight	1–5
Moderate	6–12
Severe	13–18
Very severe	19–21

Additional Assessment:

Pad test (1-hour or 24-hour): <1 g = dry; 1–10 g = mild; 11–50 g = moderate; >50 g = severe
Bladder diary (3-day): frequency, nocturia, urgency, volume voided
Post-void residual (PVR) by USS: >200 mL = abnormal voiding
Urodynamics: multi-channel cystometry confirms diagnosis type (SUI vs DO vs mixed)
Q-tip test: urethral hypermobility (SUI)

13. Endometriosis

Revised ASRM (rASRM) Classification:

Stage	Points	Description
Stage I (Minimal)	1–5	Isolated implants; no adhesions
Stage II (Mild)	6–15	Superficial implants <5 cm; few adhesions
Stage III (Moderate)	16–40	Multiple implants; endometrioma; peritubal/periovarian adhesions
Stage IV (Severe)	>40	Large endometriomas; dense adhesions; rectovaginal nodule; bowel/bladder involvement

Pain Severity:

VAS/NRS for dysmenorrhoea, deep dyspareunia, chronic pelvic pain — scored separately
EHP-30 (Endometriosis Health Profile) — QOL tool
ENZIAN classification — deep infiltrating endometriosis (DIE) staging

14. Vulval Symptoms (Pruritus Vulvae / Vulvodynia)

Severity	Criteria
Mild	Intermittent itch/discomfort; no skin changes; does not affect sleep or sexual function
Moderate	Persistent symptoms; visible skin changes (erythema, lichenification); some impact on daily activities/sexual function
Severe	Constant debilitating symptoms; significant skin pathology (lichen sclerosus with scarring, fusion, stenosis); complete inability to have intercourse; malignant transformation risk
Malignancy concern	Raised, ulcerated, or pigmented lesion; inguinal lymphadenopathy → urgent biopsy

Severity Tools:

VAS for pain/itch
DLQI (Dermatology Life Quality Index)
Biopsy — mandatory if lichen sclerosus, VIN, or suspicious lesion
Colposcopy/vulvoscopy — for detailed assessment of VIN
ISSVD classification of vulval dermatoses

Quick Reference — Severity "Red Flags" Requiring Immediate Action

Red Flag	Likely Diagnosis
Haemodynamic instability (SBP <90, HR >100)	Ruptured ectopic, massive haemorrhage
Positive βhCG + acute pelvic pain	Ectopic pregnancy until proven otherwise
Peritonism / rigid abdomen	Ruptured ectopic, TOA, perforation
Severe sepsis / septic shock	PID with TOA, septic abortion
Absent ovarian Doppler flow	Ovarian torsion — surgical emergency
PMB + endometrial thickness >4 mm	Endometrial carcinoma — urgent biopsy
Visible cervical lesion + PCB	Cervical carcinoma — urgent colposcopy/biopsy
Hb <70 g/L + ongoing bleeding	Blood transfusion + urgent intervention

No give as just the indicator , no need to divide as mild moderate severe

Severity Assessment Indicators — Gynaecology Presentations

#	Presentation	Severity Assessment Indicators
1	Menorrhagia	• Pictorial Blood Assessment Chart (PBAC) — score >100 = heavy bleeding • Haemoglobin & ferritin (iron-deficiency anaemia) • Pulse & BP (haemodynamic status) • Frequency of pad/tampon change • Presence of clots / flooding episodes • Quality of life impact (work/school absence)
2	Dysmenorrhoea	• Visual Analogue Scale (VAS) 0–10 • Verbal Numerical Rating Scale (VNRS) • Biberoglu & Behrman Score (endometriosis pain) • Response to NSAIDs (poor response = secondary cause) • Degree of work/school absence • Presence of vomiting/syncope with pain
3	Intermenstrual / Postcoital Bleeding	• Speculum — visible cervical lesion / contact bleeding • Cervical smear status & result • STI swabs (chlamydia, gonorrhoea) • Endometrial thickness on TVUSS (if >45 yrs) • Colposcopy findings • Recurrence frequency
4	Postmenopausal Bleeding	• Transvaginal USS — endometrial thickness (<4 mm = low risk; ≥4 mm → biopsy) • Pipelle endometrial biopsy result • Hysteroscopy findings (gold standard) • Risk factor burden (obesity, diabetes, HRT use, tamoxifen, Lynch syndrome) • Doppler vascularity of endometrium
5	Pelvic Inflammatory Disease	• Temperature (fever >38°C) • WBC, CRP, ESR • Sepsis-3 / qSOFA score (RR ≥22, SBP ≤100, altered mentation) • USS pelvis — tubo-ovarian abscess (TOA) • Cervical motion tenderness degree • Response to 72-hour outpatient antibiotics
6	Acute Pelvic Pain	• Shock Index (HR ÷ SBP) — >1.0 = significant haemorrhage • βhCG (mandatory first test) • Abdominal examination — guarding, rigidity, rebound • USS — free fluid (haemoperitoneum), adnexal mass • FBC & Group and Save • Haemodynamic observations (BP, HR, SpO₂)
7	Ectopic Pregnancy	• Shock Index (HR ÷ SBP) >1.0 • Serial βhCG levels & trend • USS — adnexal mass size, fetal cardiac activity, volume of free fluid • Haemoglobin trend • Presence of shoulder-tip pain / syncope (indicates haemoperitoneum)
8	Ovarian Cyst / Torsion	• Risk of Malignancy Index (RMI = M × U × CA-125) • USS Doppler flow (absent = torsion until proven otherwise) • Adnexal mass size (>5 cm = higher torsion risk) • CA-125, HE4, ROMA score • Haemodynamic observations • Duration of pain (>6–8 hours = infarction risk in torsion)
9	Subfertility	• AMH (Anti-Müllerian Hormone) — ovarian reserve (<5 pmol/L = poor) • Antral Follicle Count (AFC) on USS • Day 21 serum progesterone (>30 nmol/L = ovulatory) • WHO semen analysis parameters • rASRM staging (endometriosis) • Tubal patency (HSG / laparoscopy findings)
10	PCOS	• Modified Ferriman-Gallwey (mFG) score (≥4–6 = hirsutism) • Fasting glucose / OGTT / HbA1c • Fasting lipid profile • Free Androgen Index (FAI) / testosterone / SHBG • BMI + waist circumference • TVUSS — ovarian volume (>10 mL) & follicle count (≥20 per ovary)
11	Pelvic Organ Prolapse	• POP-Q staging (Stage 0–IV) • Post-void residual (PVR) by USS (>150–200 mL = significant) • POPDI-6 score (Pelvic Organ Prolapse Distress Inventory) • ICIQ-VS (vaginal symptom questionnaire) • Degree of voiding / bowel dysfunction
12	Urinary Incontinence	• ICIQ-UI Short Form score (1–5 slight → 19–21 very severe) • Pad test — 1-hour or 24-hour (1–10 g mild; >50 g severe) • 3-day bladder diary (frequency, nocturia, urgency, volumes) • Post-void residual (PVR) • Urodynamic studies (multi-channel cystometry)
13	Endometriosis	• rASRM classification score (Stage I–IV, scored at laparoscopy) • ENZIAN score (deep infiltrating endometriosis) • VAS for dysmenorrhoea, deep dyspareunia & chronic pelvic pain (scored separately) • EHP-30 (Endometriosis Health Profile — QOL) • CA-125 (moderately elevated in Stage III–IV)
14	Vulval Symptoms	• VAS for itch / pain intensity • DLQI (Dermatology Life Quality Index) • Vulvoscopy / colposcopy findings • Biopsy result (lichen sclerosus, VIN, SCC) • ISSVD dermatosis classification • Inguinal lymph node status (malignancy)

Give me a table which include- mechanism of action, indication , maximum and minimum doses, side effects , treatment for side effects, monitoring and interaction of these drugs.. methyldopa, labetalol, nifedipine, nitroglycerin,hydralazine, prozasin

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

Here is the comprehensive drug table:

Antihypertensive Drugs — Comprehensive Reference Table

1. Methyldopa

Parameter	Details
Mechanism of Action	Central α2-adrenergic agonist → stimulates α2 receptors in brainstem → reduces sympathetic outflow → decreases peripheral vascular resistance, heart rate, and cardiac output
Indications	Hypertension in pregnancy (drug of choice for chronic hypertension in pregnancy); essential hypertension
Minimum Dose	250 mg twice daily (oral)
Maximum Dose	3 g/day (oral); IV: 250–500 mg every 6 hours (max 1 g every 6 hours)
Side Effects	Sedation, drowsiness, fatigue, depression, dry mouth, postural hypotension, bradycardia, haemolytic anaemia (Coombs positive), hepatotoxicity, galactorrhoea (hyperprolactinaemia), nasal congestion, impotence
Treatment of Side Effects	Sedation → dose reduction or switch drug; Haemolytic anaemia → stop drug, corticosteroids if severe; Hepatotoxicity → stop drug, liver function monitoring; Depression → switch to alternative antihypertensive; Postural hypotension → reduce dose, advise slow positional changes
Monitoring	BP, HR, FBC (Coombs test at 6–12 months), LFTs (baseline and periodically), direct antiglobulin test (DAT), mental health assessment
Interactions	MAOIs → hypertensive crisis; Lithium → lithium toxicity; Anaesthetics → enhanced hypotension; Antidepressants (TCAs) → reduced antihypertensive effect; Levodopa → reduced dopaminergic effect, additive hypotension; Iron supplements → reduced methyldopa absorption (separate by 2 hours)

2. Labetalol

Parameter	Details
Mechanism of Action	Combined non-selective β-adrenergic blocker + selective α1-adrenergic blocker (β:α blocking ratio oral 3:1, IV 7:1) → reduces heart rate, cardiac output, and peripheral vascular resistance
Indications	Acute severe hypertension in pregnancy (first-line IV agent); hypertensive emergencies; chronic hypertension; angina; post-MI hypertension
Minimum Dose	Oral: 100 mg twice daily; IV bolus: 20 mg slow IV (over 2 min)
Maximum Dose	Oral: 2400 mg/day; IV bolus: 300 mg total cumulative dose; IV infusion: 160 mg/hour
Side Effects	Bradycardia, bronchospasm, postural hypotension, fatigue, cold extremities, nausea, scalp tingling/paraesthesia, hepatotoxicity (rare), neonatal bradycardia and hypoglycaemia (in pregnancy), masking of hypoglycaemia symptoms
Treatment of Side Effects	Bradycardia → atropine 0.5–1 mg IV; Bronchospasm → salbutamol nebuliser (avoid labetalol in asthma); Hypotension → IV fluids, glucagon 1–2 mg IV (β-blocker reversal); Neonatal bradycardia → neonatal team review, monitoring
Monitoring	BP (continuous during IV therapy), HR, RR, blood glucose (neonates), LFTs (long-term oral use), signs of bronchospasm
Interactions	Verapamil/diltiazem → severe bradycardia and AV block (avoid combination); Insulin/oral hypoglycaemics → masks hypoglycaemia; Anaesthetic agents → enhanced hypotension; Cimetidine → increased labetalol levels; NSAIDs → reduced antihypertensive effect; Clonidine → rebound hypertension on clonidine withdrawal

3. Nifedipine

Parameter	Details
Mechanism of Action	Dihydropyridine calcium channel blocker (L-type) → blocks voltage-gated calcium channels in vascular smooth muscle → vasodilation → reduces peripheral vascular resistance and BP; also used as a tocolytic (relaxes uterine smooth muscle)
Indications	Hypertension in pregnancy (oral, for acute and chronic); hypertensive emergencies; angina (stable and vasospastic); Raynaud's phenomenon; preterm labour (tocolysis)
Minimum Dose	Immediate-release: 5 mg oral/sublingual; Modified-release: 10 mg once daily
Maximum Dose	Immediate-release: 90 mg/day; Modified-release: 90–120 mg/day
Side Effects	Reflex tachycardia, flushing, headache, ankle oedema, dizziness, gingival hyperplasia (long-term), nausea, palpitations; sublingual use → precipitous BP drop (avoid sublingual in pregnancy)
Treatment of Side Effects	Ankle oedema → elevation, dose reduction; Headache/flushing → usually resolves; reassure, consider dose reduction; Reflex tachycardia → add β-blocker if not contraindicated; Gingival hyperplasia → good oral hygiene, dental review, switch drug if severe
Monitoring	BP, HR (reflex tachycardia), ankle oedema, fetal heart rate (in pregnancy), blood glucose (in diabetics)
Interactions	Grapefruit juice → increased nifedipine levels (inhibits CYP3A4) — avoid; Magnesium sulphate (in pregnancy) → potentiates hypotension and neuromuscular blockade; Beta-blockers → may worsen cardiac failure; Digoxin → increased digoxin levels; Rifampicin → reduced nifedipine levels; Phenytoin/carbamazepine → reduced nifedipine levels; Azole antifungals → increased nifedipine toxicity

4. Nitroglycerin (Glyceryl Trinitrate / GTN)

Parameter	Details
Mechanism of Action	Organic nitrate → converted to nitric oxide (NO) → activates guanylate cyclase → increases cGMP → vascular smooth muscle relaxation → venodilation (primarily) and arterial dilation → reduces preload and afterload; coronary vasodilation
Indications	Hypertensive emergencies (especially with pulmonary oedema, ACS); acute angina (sublingual); unstable angina; acute MI; acute pulmonary oedema; perioperative hypertension
Minimum Dose	Sublingual: 0.3 mg PRN; IV infusion: 5–10 mcg/min
Maximum Dose	Sublingual: 3 doses (0.3–0.6 mg) in 15 min; IV infusion: up to 200–400 mcg/min (titrated)
Side Effects	Headache (most common), postural hypotension, reflex tachycardia, flushing, dizziness, methaemoglobinaemia (high doses/prolonged IV), tolerance (with continuous use >24–48 hours), contact dermatitis (patches)
Treatment of Side Effects	Headache → paracetamol, dose reduction; Hypotension → IV fluids, reduce infusion rate, leg elevation; Methaemoglobinaemia → methylene blue 1–2 mg/kg IV; Tolerance → nitrate-free interval (8–12 hours/day)
Monitoring	Continuous BP and HR monitoring (IV use), SpO₂, methaemoglobin levels (prolonged IV), headache assessment, ECG (in ACS context)
Interactions	Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) → absolute contraindication — severe life-threatening hypotension; Antihypertensives → additive hypotension; Alcohol → potentiates hypotension; Heparin → IV GTN reduces anticoagulant effect of heparin; Ergotamine → increases ergotamine absorption and vasospasm

5. Hydralazine

Parameter	Details
Mechanism of Action	Direct-acting peripheral vasodilator → relaxes arteriolar smooth muscle (exact mechanism unclear — possibly interferes with calcium release) → reduces peripheral vascular resistance → reduces afterload; does not dilate veins significantly
Indications	Acute severe hypertension in pregnancy (IV, when labetalol unavailable/contraindicated); hypertensive emergencies; chronic hypertension (adjunct); heart failure (combined with nitrates when ACE inhibitors not tolerated)
Minimum Dose	Oral: 25 mg twice daily; IV bolus: 5 mg slow IV
Maximum Dose	Oral: 200 mg/day (up to 300 mg/day in heart failure); IV: 20 mg per bolus, repeat every 20–30 min; total 40–60 mg per episode
Side Effects	Reflex tachycardia, palpitations, headache, flushing, nausea, fluid retention/oedema, drug-induced lupus erythematosus (DILE) — especially at high doses >200 mg/day or slow acetylators, peripheral neuropathy (pyridoxine deficiency), nasal congestion, angina precipitation
Treatment of Side Effects	Reflex tachycardia → add beta-blocker; Fluid retention → diuretic; DILE → stop hydralazine, hydroxychloroquine or corticosteroids if severe; Peripheral neuropathy → pyridoxine (Vitamin B6) supplementation; Angina → reduce dose, add nitrate
Monitoring	BP (continuous during IV), HR, ANA titre (drug-induced lupus — baseline and 6-monthly on long-term therapy), FBC, urinalysis (DILE), acetylator status (if available)
Interactions	MAOIs → severe hypotension (avoid); Beta-blockers → used therapeutically to counter reflex tachycardia but may cause additive hypotension; NSAIDs → reduced antihypertensive effect; Diazoxide → severe hypotension; Anaesthetic agents → enhanced hypotension; Adrenaline → exaggerated vasopressor response

6. Prazosin

Parameter	Details
Mechanism of Action	Selective competitive α1-adrenergic receptor blocker → blocks post-synaptic α1 receptors in vascular smooth muscle → arteriolar and venous dilation → reduces peripheral vascular resistance and preload; does not block pre-synaptic α2 receptors (no reflex noradrenaline release)
Indications	Hypertension (adjunct); benign prostatic hyperplasia (BPH); Raynaud's phenomenon; phaeochromocytoma (short-term, with β-blocker); heart failure (adjunct); scorpion envenomation (in some regions)
Minimum Dose	0.5 mg at night (test dose — to assess first-dose effect)
Maximum Dose	20 mg/day in divided doses (hypertension); BPH: up to 10 mg/day
Side Effects	First-dose hypotension/syncope (characteristic — occurs 30–90 min after first dose), dizziness, drowsiness, headache, palpitations, nasal congestion, urinary incontinence (in women), oedema, priapism (rare), intraoperative floppy iris syndrome (IFIS) during cataract surgery
Treatment of Side Effects	First-dose hypotension → lay patient flat, IV fluids if severe; advise patient to take first dose at night in bed; Priapism → urgent urology referral; IFIS → inform ophthalmologist before any eye surgery; Oedema → diuretic addition
Monitoring	BP (lying and standing — orthostatic hypotension), HR, symptom assessment (dizziness, syncope), urinary symptoms (in BPH), ophthalmic history before surgery
Interactions	Other antihypertensives / diuretics → additive hypotension (especially first dose); PDE-5 inhibitors (sildenafil, tadalafil) → severe hypotension (caution/avoid); Beta-blockers → enhanced first-dose hypotension; Verapamil → increased prazosin levels; NSAIDs → reduced antihypertensive effect; Indomethacin → reduced prazosin effect

Quick Comparison Summary

Drug	Class	Key Use in Pregnancy	Route	Main Monitoring
Methyldopa	Central α2 agonist	Chronic HTN (drug of choice)	Oral / IV	Coombs test, LFTs
Labetalol	α + β blocker	Acute severe HTN (IV first-line)	Oral / IV	BP, HR, LFTs
Nifedipine	Ca²⁺ channel blocker	Acute & chronic HTN, tocolysis	Oral	BP, HR, oedema
Nitroglycerin	Nitrate / NO donor	Hypertensive emergency + pulmonary oedema	IV / SL / patch	BP, HR, metHb
Hydralazine	Direct vasodilator	Acute severe HTN (IV alternative)	Oral / IV	BP, ANA, FBC
Prazosin	α1 blocker	Not first-line in pregnancy	Oral	BP (postural), syncope

Refer these and slcog guidelines and make me a complete obstetric cycle with special things to do in each time on iron deficiency anaemia. Make it as a pdf doc and as well as 2 presentation slides as well

Reading File

Running Command

Writing File

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

This is a shared conversation. Sign in to Orris to start your own chat.